Document is current
Any future updates will be listed below
-
Authors
Lankina, A.
Hargreaves, A.
Lui, W. T.
Kropff, B.
Wei, A.
Breuer, J.
White, R. E.
Thomas, M.
Griffiths, P. D.
Reeves, M. B.
-
Funding
Funding for this research was provided by:
Biotechnology and Biological Sciences Research Council (BB/T008709/1, BB/T008709/1)
Medical Research Council (MR/W006774/1, MR/W006774/1)
Wellcome Trust (WT/204870/Z/16/Z, WT/204870/Z/16/Z, WT/204870/Z/16/Z)
Kidney Research UK (RP_008_20231101)
- License Information
-
More Information
Article History
Received: 10 July 2025
Accepted: 6 November 2025
First Online: 5 December 2025
Competing interests
: P.D.G. and M.R. are co-inventors on WO Patent WO 2022/129937A1, assigned to University College London (UCL), entitled ‘hCMV antibody and vaccine target’, that deals with a novel antigenic domain in HCMV glycoprotein B (gB). M.B.R. has led sponsored research funded by Moderna. The authors declare no other competing interests.
